Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications

被引:33
|
作者
Gogna, R. [1 ]
Madan, E. [1 ]
Kuppusamy, P. [2 ]
Pati, U. [1 ]
机构
[1] Jawaharlal Nehru Univ, Sch Biotechnol, Transcript & Human Biol Lab, New Delhi 110067, India
[2] Ohio State Univ, Dept Internal Med, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
来源
CELL DEATH & DISEASE | 2012年 / 3卷
关键词
p53; hypoxia; tumor regression; oxygenation; mutant rescue; HYPERBARIC-OXYGEN THERAPY; CELLS; CANCER; RADIOTHERAPY; PATHWAYS; GROWTH; SENSITIVITY; EXPRESSION; APOPTOSIS; DAMAGE;
D O I
10.1038/cddis.2012.15
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Hypoxic tumors are resistant to conventional therapies through indirect mechanisms such as the selection of resistant phenotype under chronic hypoxia. Hyperbaric oxygen (HBO) therapy has been shown to increase oxygen level and induce apoptosis in hypoxic tumor. However, it could produce significant adverse effects including oxygen toxic seizures and severe radiation tissue injury due to high pressure. We have shown that repeated oxygenation at 30% O-2 (1 atmospheres absolute) results in significant regression of MCF-7 tumor xenografts without any adverse effect. In MCF-7 cells, re-oxygenation showed an eightfold increase in cellular apoptosis. Both in hypoxic tumor and in hypoxic cells, that exclusively favor p53 to exist in mutant conformation, re-oxygenation restores p53 wild-type conformation. The oxygen-mediated rescue of mutant p53 followed by its trans-activation is responsible for the induction of p53-downstream apoptotic, cell-cycle arrest and DNA-repair genes. Further, p53 trans-activation may thus be due to its post-translational modifications as a result of re-oxygenation. We have thus concluded that oxygen therapy without pressure, as opposed to HBO therapy, may be ideal for hypoxic tumor regression, which functions through oxygen-mediated rescue of mutant p53 followed by induction of apoptosis. Cell Death and Disease (2012) 3, e286; doi:10.1038/cddis.2012.15; published online 15 March 2012
引用
收藏
页码:e286 / e286
页数:7
相关论文
共 25 条
  • [21] Disruption of the MDM2-p53 interaction synergizes with MEK inhibition to induce cell death and promote tumor regression in p53 wild-type, Ras or Raf-mutant tumor models
    Meaux, Isabelle
    Nicolas, Jean-Paul
    Rowley, Steve
    Sidhu, Sukhvinder
    Herve, Francoise
    Dassencourt, Laurent
    Windenberger, Fanny
    Gorge-Bernat, Dimitri
    Pannier, Pascal
    Bergstrom, Donald
    Debussche, Laurent
    Watters, James
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescence
    Gammazza, Antonella Marino
    Campanella, Claudia
    Barone, Rosario
    Bavisotto, Celeste Caruso
    Gorska, Magdalena
    Wozniak, Michal
    Carini, Francesco
    Cappello, Francesco
    D'Anneo, Antonella
    Lauricella, Marianna
    Zummo, Giovanni
    de Macario, Everly Conway
    Macario, Alberto J. L.
    Di Felice, Valentina
    CANCER LETTERS, 2017, 385 : 75 - 86
  • [23] Celecoxib enhances the response of tumor cells to cisplatin through upregulating PUMA in non–small cell lung cancer carrying wild-type p53
    Yuxuan Xiao
    Ziyu Wang
    Meng Gu
    Jinjing Tan
    Weiying Li
    Oncology and Translational Medicine, 2024, 10 (02) : 79 - 86
  • [24] Combination therapy with IL-2 and wild-type p53 expressed by Ad-vectors induces tumor regression in vivo without cytokine related toxicity
    Putzer, BM
    Bramson, JL
    Addison, CL
    Muller, WJ
    Graham, FL
    CANCER GENE THERAPY, 1997, 4 (06) : P137 - P137
  • [25] Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1
    North, S
    Pluquet, O
    Maurici, D
    El Ghissassi, F
    Hainaut, P
    MOLECULAR CARCINOGENESIS, 2002, 33 (03) : 181 - 188